📊 GRAL Key Takeaways
Is GRAIL, Inc. (GRAL) a Good Investment?
GRAL is a pre-profitability clinical diagnostics company burning capital at an unsustainable rate, with operating losses of $135.8M vastly exceeding revenues of $40.8M. While the strong $2.5B balance sheet provides temporary runway, negative cash flow of $87.5M annually and an unclear path to profitability make this a high-risk investment with limited upside unless revenue accelerates dramatically.
GRAIL shows modest revenue growth but remains far from profitability, with extremely negative operating and free cash flow margins and a large operating loss. A strong, debt‑free balance sheet and ample liquidity provide runway, yet current burn suggests a need for material scaling and cost improvements to reach breakeven. Without clear evidence of improving unit economics, the risk of future funding needs or dilution remains elevated.
Why Buy GRAIL, Inc. Stock? GRAL Key Strengths
- Strong balance sheet with $2.5B stockholders' equity and zero material long-term debt
- Exceptional liquidity position with 11.74x current ratio providing extended operational runway
- Revenue growth of 17.2% YoY demonstrates customer traction and market demand
- Net income losses improved 79.9% YoY, indicating operational progress toward profitability
- Debt-free balance sheet with high liquidity (11.97x current ratio)
- Improving net loss and EPS on a year-over-year basis
- Low capital intensity (minimal capex) enabling focus on operating leverage
GRAL Stock Risks: GRAIL, Inc. Investment Risks
- Severe annual cash burn of $87.5M with negative operating cash flow exhausts $69.3M cash reserves in ~9 months
- Operating losses of -$135.8M against $40.8M revenue (-332.9% margin) indicates fundamentally unprofitable business model
- Likely requires dilutive financing to continue operations without major revenue acceleration
- Negative returns on capital (ROE -3.7%, ROA -3.3%) show ongoing value destruction
- Clinical diagnostics sector requires sustained R&D investment with uncertain regulatory approval and commercialization timelines
- Severe cash burn and negative FCF margin (-203.8%)
- Extremely negative operating margin (-382%) indicating weak unit economics
- Potential dilution or funding needs if growth and margins do not improve
Key Metrics to Watch
- Operating cash flow and free cash flow progression toward positive territory
- Revenue growth rate and gross margin expansion as diagnostic volumes scale
- Cash runway duration and timing of next capital requirement
- Operating margin improvement toward breakeven
- Form 4 insider transaction patterns (12 filings in 90 days)
- Operating cash flow (burn and runway)
- Revenue growth and operating margin improvement
GRAIL, Inc. (GRAL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.74x current ratio provides a solid financial cushion.
GRAL Profit Margin, ROE & Profitability Analysis
GRAL vs Healthcare Sector: How GRAIL, Inc. Compares
How GRAIL, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GRAIL, Inc. Stock Overvalued? GRAL Valuation Analysis 2026
Based on fundamental analysis, GRAIL, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GRAIL, Inc. Balance Sheet: GRAL Debt, Cash & Liquidity
GRAL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GRAIL, Inc.'s revenue has grown significantly by 17% over the 5-year period, indicating strong business expansion. The most recent EPS of $-47.21 indicates the company is currently unprofitable.
GRAL Revenue Growth, EPS Growth & YoY Performance
GRAL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $31.8M | -$93.2M | $-2.29 |
| Q3 2025 | $28.7M | -$89.0M | $-2.46 |
| Q2 2025 | $32.0M | -$106.2M | $-3.18 |
| Q1 2025 | $26.7M | -$106.2M | $-3.10 |
| Q3 2024 | $20.7M | -$125.7M | $-3.94 |
| Q2 2024 | $22.4M | -$193.0M | $-6.22 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GRAIL, Inc. Dividends, Buybacks & Capital Allocation
GRAL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GRAIL, Inc. (CIK: 0001699031)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GRAL
What is the AI rating for GRAL?
GRAIL, Inc. (GRAL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GRAL's key strengths?
Claude: Strong balance sheet with $2.5B stockholders' equity and zero material long-term debt. Exceptional liquidity position with 11.74x current ratio providing extended operational runway. ChatGPT: Debt-free balance sheet with high liquidity (11.97x current ratio). Improving net loss and EPS on a year-over-year basis.
What are the risks of investing in GRAL?
Claude: Severe annual cash burn of $87.5M with negative operating cash flow exhausts $69.3M cash reserves in ~9 months. Operating losses of -$135.8M against $40.8M revenue (-332.9% margin) indicates fundamentally unprofitable business model. ChatGPT: Severe cash burn and negative FCF margin (-203.8%). Extremely negative operating margin (-382%) indicating weak unit economics.
What is GRAL's revenue and growth?
GRAIL, Inc. reported revenue of $40.8M.
Does GRAL pay dividends?
GRAIL, Inc. does not currently pay dividends.
Where can I find GRAL SEC filings?
Official SEC filings for GRAIL, Inc. (CIK: 0001699031) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GRAL's EPS?
GRAIL, Inc. has a diluted EPS of $-2.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GRAL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, GRAIL, Inc. has a SELL rating with 71% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GRAL stock overvalued or undervalued?
Valuation metrics for GRAL: ROE of -3.7% (sector avg: 15%), net margin of -228.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GRAL stock in 2026?
Our dual AI analysis gives GRAIL, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GRAL's free cash flow?
GRAIL, Inc.'s operating cash flow is $-87.0M, with capital expenditures of $503.0K. FCF margin is -214.5%.
How does GRAL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -228.5% (avg: 12%), ROE -3.7% (avg: 15%), current ratio 11.74 (avg: 2).